New book by Larry Connors Click here Improve your trading - See how
The children participating in the Diamyd(r) study are at high risk of developing type 1 diabetes. It has been concluded that they all have an ongoing autoimmune disease process, where their insulin-producing cells are being destroyed by their own immune system. If the destruction is not stopped, it can with time lead to type 1 diabetes. Today there is no treatment that can prevent the progress of the disease.
"We are hoping that treatment with Diamyd(r) will alter this situation, so that we in the future could help children already before they develop type 1 diabetes," says Helena Elding Larsson, pediatrician at the UMAS university hospital in Malmo and researcher at Lund University. "So far three children have been treated with two injections each of the Diamyd(r) vaccine or placebo," states Elding Larsson.
The objective is to evaluate whether vaccination with Diamyd(r) could delay or halt the progress of the disease, so that the children do not develop type 1 diabetes. Diamyd Medical reported on March 4 this year that the Swedish Medical Products Agency had approved the study.
"If the Diamyd(r) vaccine would be able to prevent or delay this serious disease, which primarily affects children and adolescents, we are facing a medical breakthrough," says Elisabeth Lindner, President and CEO of Diamyd Medical.
The study, which is the first of its kind, is double-blind and placebo-controlled and includes a total of 50 children ages four and above. Half of the children will receive two injections of the Diamyd(r) vaccine, and half will receive placebo (a non-active medication).
In type 1 diabetes, the children's blood sugar must be checked and insulin injections must be taken several times a day, while careful attention must be paid to diet and exercise. Type 1 diabetes is a chronic disease for which there is currently no cure. The disease must be strictly controlled in order to avoid the serious complications associated with diabetes.
A few studies aiming to prevent type 1 diabetes have been conducted worldwide, but no one has yet been able to affect the progress of the disease. Researchers have for a long time been convinced that the active substance in Diamyd(r) (GAD) may prevent type 1 diabetes. Now the development of the drug has progressed far enough to initiate a prevention study in children.
For additional information, please contact: Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.) Tel: +46 (0)8 6610026 For pictures and press material, please contact: Alexandra Fleetwood, Director Communications Diamyd Medical AB (publ.), alexandra.fleetwood@diamyd.com Tel: +46 (0)8 661 0026
About Diamyd Medical
Diamyd Medical is a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd(r) for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has initiated clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease. The company currently has three clinical-phase products.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY | Quote | Chart | News | PowerRating) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the company's website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.
VAT no: SE556530-142001.
(www.omxnordicexchange.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Diamyd Medical AB
Diamyd Medical AB
+46 (0)8 6610026
Fax: +46 (0)8 661 63 68
Linnegatan 89 B, SE-115 23
Stockholm, Sweden
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.